Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
© 2023 British Society for Haematology and John Wiley & Sons Ltd..
This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas. Of these patients, 22 (43%) were enrolled in clinical trials (glofitamab or loncastuximab tesirine + ibrutinib), whereas 29 received standard therapies (lenalidomide [Len], checkpoint inhibitors [CPIs], ibrutinib [I], chemoimmunotherapy and radiotherapy) or supportive care. Overall, 26 of 39 (67%) treated patients received a treatment based on immunotherapy (glofitamab, CPI, Len) that was mainly represented by bispecific antibody (n = 18). In this subgroup, plasma samples were collected and analysed for circulating tumour DNA (ctDNA) using cancer-personalized profiling by deep sequencing (CAPP-seq). The study found that patients with high ctDNA had poor outcomes. At a median follow-up of 11.7 months, the estimated 12-month overall survival (OS) was 35%. Factors adversely affecting the prognosis in the multivariable model were the absence of response to CAR T-cell therapy (HR: 3.08; p = 0.0109) and a diagnosis other than PMBCL and t-FL (HR: 4.54; p = 0.0069). The outcome of patients failing CAR T cells is poor and requires further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
British journal of haematology - 204(2024), 1 vom: 27. Jan., Seite 151-159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dodero, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD19 |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.19057 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361882947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361882947 | ||
| 003 | DE-627 | ||
| 005 | 20240306232416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19057 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM361882947 | ||
| 035 | |a (NLM)37690811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dodero, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas. Of these patients, 22 (43%) were enrolled in clinical trials (glofitamab or loncastuximab tesirine + ibrutinib), whereas 29 received standard therapies (lenalidomide [Len], checkpoint inhibitors [CPIs], ibrutinib [I], chemoimmunotherapy and radiotherapy) or supportive care. Overall, 26 of 39 (67%) treated patients received a treatment based on immunotherapy (glofitamab, CPI, Len) that was mainly represented by bispecific antibody (n = 18). In this subgroup, plasma samples were collected and analysed for circulating tumour DNA (ctDNA) using cancer-personalized profiling by deep sequencing (CAPP-seq). The study found that patients with high ctDNA had poor outcomes. At a median follow-up of 11.7 months, the estimated 12-month overall survival (OS) was 35%. Factors adversely affecting the prognosis in the multivariable model were the absence of response to CAR T-cell therapy (HR: 3.08; p = 0.0109) and a diagnosis other than PMBCL and t-FL (HR: 4.54; p = 0.0069). The outcome of patients failing CAR T cells is poor and requires further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAR T cells | |
| 650 | 4 | |a bispecific antibodies | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a refractory large B-cell lymphoma | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Bramanti, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Di Trani, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Pennisi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Ljevar, Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Chiappella, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Massimo, Magagnoli |e verfasserin |4 aut | |
| 700 | 1 | |a Guidetti, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Corrado, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Nierychlewska, Paulina Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Di Rocco, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Daoud, Rahal |e verfasserin |4 aut | |
| 700 | 1 | |a De Philippis, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Carlo-Stella, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 204(2024), 1 vom: 27. Jan., Seite 151-159 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2024 |g number:1 |g day:27 |g month:01 |g pages:151-159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19057 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2024 |e 1 |b 27 |c 01 |h 151-159 | ||